Invasive growth: a MET-driven genetic programme for cancer and stem cells

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Nature Reviews. Cancer

• Publication date

  2006-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc1912PMID 16862193
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cells enriched in markers of neural tissue-committed stem cells reside in the bone marrow and are mobilized into the peripheral blood following stroke

  2006cited by this paper
• Hepatocyte Growth Factor Effects on Mesenchymal Stem Cells: Proliferation, Migration, and Differentiation

  2006cited by this paper
• Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

  2006cited by this paper
• Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity.

  2006cited by this paper
• Hypoxia requires notch signaling to maintain the undifferentiated cell state.

  2005cited by this paper
• Cancer therapy: can the challenge be MET?

  2005cited by this paper
• Molecular requirements for epithelial-mesenchymal transition during tumor progression.

  2005cited by this paper
• Genes that mediate breast cancer metastasis to lung

  2005cited by this paper
• Identification of bronchioalveolar stem cells in normal lung and lung cancer.

  2005cited by this paper
• Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF‐1–CXCR4 Axis

  2005cited by this paper
• Migrating cancer stem cells — an integrated concept of malignant tumour progression

  2005cited by this paper
• Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness.

  2005cited by this paper
• Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells.

  2005cited by this paper
• Leukaemia stem cells and the evolution of cancer-stem-cell research

  2005cited by this paper
• The MET oncogene drives a genetic programme linking cancer to haemostasis

  2005cited by this paper
• Tumour stem cells and drug resistance

  2005cited by this paper
• Negative Feedback Regulation of Met-Dependent Invasive Growth by Notch

  2005cited by this paper
• Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.

  2005cited by this paper
• Lasting longer without oxygen: The influence of hypoxia on Notch signaling.

  2005cited by this paper
• Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue.

  2005cited by this paper
• Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?

  2005cited by this paper
• Mechanisms of Disease: the impact of antithrombotic therapy in cancer patients

  2005cited by this paper
• Cardiac Stem Cells Possess Growth Factor-Receptor Systems That After Activation Regenerate the Infarcted Myocardium, Improving Ventricular Function and Long-Term Survival

  2005cited by this paper
• Cell migration during gastrulation.

  2005cited by this paper
• The fallacy of epithelial mesenchymal transition in neoplasia.

  2005cited by this paper
• CXCR4 and Gab1 cooperate to control the development of migrating muscle progenitor cells.

  2005cited by this paper
• A unique population of bone marrow cells migrates to skeletal muscle via hepatocyte growth factor/c-met axis

  2005cited by this paper
• PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.

  2005cited by this paper
• Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer Patients

  2005cited by this paper
• An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice.

  2004cited by this paper
• Functional Expression of HGF and HGF Receptor/c‐met in Adult Human Mesenchymal Stem Cells Suggests a Role in Cell Mobilization, Tissue Repair, and Wound Healing

  2004cited by this paper
• Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions.

  2004cited by this paper
• Tissue repair and stem cell renewal in carcinogenesis

  2004cited by this paper
• Identification of human brain tumour initiating cells

  2004cited by this paper
• Friends or foes — bipolar effects of the tumour stroma in cancer

  2004cited by this paper
• Increased expression of Met protein is associated with up‐regulation of hypoxia inducible factor‐1 (HIF‐1) in tumour cells in papillary carcinoma of the thyroid

  2004cited by this paper
• Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting.

  2004cited by this paper
• Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition

  2004cited by this paper
• Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

  2004cited by this paper
• Targeting the tumor and its microenvironment by a dual-function decoy Met receptor.

  2004cited by this paper
• Hepatocyte Growth Factor/c-Met Signaling Promotes the Progression of Experimental Human Neuroblastomas

  2004cited by this paper
• Cells Expressing Early Cardiac Markers Reside in the Bone Marrow and Are Mobilized Into the Peripheral Blood After Myocardial Infarction

  2004cited by this paper
• Interplay between scatter factor receptors and B plexins controls invasive growth

  2004cited by this paper
• The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration.

  2003cited by this paper
• Diversity of hepatic stem cells in the fetal and adult liver.

  2003cited by this paper
• Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways

  2003cited by this paper
• Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

  2003cited by this paper
• c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases.

  2003cited by this paper
• Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development.

  2003cited by this paper
• Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL

  2003cited by this paper
• Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.

  2003cited by this paper
• How to make tubes: signaling by the Met receptor tyrosine kinase.

  2003cited by this paper
• Angiogenesis inhibitors: motivators of metastasis?

  2003cited by this paper
• Expression of c-met Tyrosine Kinase Receptor Is Biologically and Prognostically Relevant for Primary Cutaneous Malignant Melanomas

  2003cited by this paper
• Met, metastasis, motility and more

  2003cited by this paper
• The MSP Receptor Regulates α6β4 and α3β1 Integrins via 14-3-3 Proteins in Keratinocyte Migration

  2003cited by this paper
• Targeting HIF-1 for cancer therapy

  2003cited by this paper
• Prospective identification of tumorigenic breast cancer cells

  2003cited by this paper
• Applying the principles of stem-cell biology to cancer

  2003cited by this paper
• Tyrosine kinase signal specificity: lessons from the HGF receptor.

  2003cited by this paper
• A multigenic program mediating breast cancer metastasis to bone.

  2003cited by this paper
• HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver.

  2003cited by this paper
• Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer.

  2002cited by this paper
• CD44 is required for two consecutive steps in HGF/c-Met signaling.

  2002cited by this paper
• Stem-cell origin of metastasis and heterogeneity in solid tumours.

  2002cited by this paper
• Epithelial–mesenchymal transitions in tumour progression

  2002cited by this paper
• Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.

  2002cited by this paper
• Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability.

  2002cited by this paper
• Clonal identification and characterization of self-renewing pluripotent stem cells in the developing liver

  2002cited by this paper
• Tumours : wounds that do not heal.

  2002cited by this paper
• Hypoxia — a key regulatory factor in tumour growth

  2002cited by this paper
• Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis

  2002cited by this paper
• The Semaphorin 4D receptor controls invasive growth by coupling with Met

  2002cited by this paper
• Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice.

  2002cited by this paper
• The -Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells

  2002cited by this paper
• The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells.

  2002cited by this paper
• Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas

  2002cited by this paper
• Scatter-factor and semaphorin receptors: cell signalling for invasive growth

  2002cited by this paper
• c-Met Expression in Gastric Cancer with Liver Metastasis

  2002cited by this paper
• Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.

  2002cited by this paper
• Involvement of chemokine receptors in breast cancer metastasis

  2001cited by this paper
• Epidemiology of Thrombosis in Cancer

  2001cited by this paper
• A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth.

  2001cited by this paper
• The Role of the Hemostatic System in Tumor Growth, Metastasis, and Angiogenesis: Tissue factor is a Bifunctional Molecule Capable of Inducing Both Fibrin Deposition and Angiogenesis in Cancer

  2001cited by this paper
• Stem cells, cancer, and cancer stem cells

  2001cited by this paper
• Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice

  2001cited by this paper
• A Signaling Adapter Function for 6 4 Integrin in the Control of HGF-Dependent Invasive Growth

  2001cited by this paper
• Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways.

  2001cited by this paper
• Signaling of Hepatocyte Growth Factor/Scatter Factor (HGF) to the Small GTPase Rap1 via the Large Docking Protein Gab1 and the Adapter Protein CRKL*

  2000cited by this paper
• Coupling of Gab1 to C-Met, Grb2, and Shp2 Mediates Biological Responses

  2000cited by this paper
• Increased expression of HGF and c-met in rat small intestine during recovery from methotrexate-induced mucositis

  2000cited by this paper
• Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis

  2000cited by this paper
• Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein

  2000cited by this paper
• The Tyrosine Phosphatase SHP-2 Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase

  2000cited by this paper
• Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

  2000cited by this paper
• Hepatocyte growth factor, a versatile signal for developing neurons

  1999cited by this paper
• Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

  1999cited by this paper
• Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.

  1999cited by this paper
• Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy.

  1999cited by this paper
• Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates.

  1999cited by this paper

• Recent Advances in Pyridine and Pyrimidine Based Scaffolds as c-Met Kinase Inhibitors for Cancer Therapy: Biological Insights, Docking and SAR

  2026cites this paper
• Sex and gender differences during the lung lifespan: unveiling a pivotal impact

  2025cites this paper
• From COPD to Smoke-Related Arteriopathy: The Mechanical and Immune–Inflammatory Landscape Underlying Lung Cancer Distant Spreading—A Narrative Review

  2025cites this paper
• MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation

  2025cites this paper
• Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy.

  2025cites this paper
• Signalling pathways in hepatocellular carcinoma (HCC) metastasis and invasion: Molecular mechanisms and therapeutic implications

  2025cites this paper
• The integrated stress response drives MET oncogene overexpression in cancers

  2025cites this paper
• ADT increases prostate cancer cell invasion via altering AR/SALL4/SOX2-OCT4 stem cell signaling

  2025cites this paper
• The Janus framework of the integrated stress response: from homeostasis to maladaptation

  2025cites this paper
• Activation of the Coagulation Cascade as a Universal Danger Sign

  2025cites this paper
• Identification of a 7H-pyrrolo[2,3-d]pyrimidin derivatives as selective type II c-Met/Axl inhibitors with potent antitumor efficacy.

  2025cites this paper
• Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions

  2024cites this paper
• Single-cell chromatin accessibility analysis reveals the epigenetic basis and signature transcription factors for the molecular subtypes of colorectal cancers.

  2024cites this paper
• Activated Gab1 drives hepatocyte proliferation and anti-apoptosis in liver fibrosis via potential involvement of the HGF/c-Met signaling axis

  2024cites this paper
• Emerging therapies targeting growth factors in hepatocellular carcinoma

  2024cites this paper
• Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling

  2024cites this paper
• Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments—An Overview

  2024cites this paper
• The MET Oncogene: An Update on Targeting Strategies

  2024cites this paper
• Invasiveness modulation of glioma cells by copper complex-loaded nanoarchitectures.

  2024cites this paper
• The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy

  2024cites this paper
• Targeted therapies in hepatocellular carcinoma: past, present, and future

  2024cites this paper
• Lung bronchiectasisas a paradigm of the interplay between infection and colonization on plastic modulation of the pre-metastatic niche

  2024cites this paper
• Switchable DNA Catalysts for Proximity Labeling at Sites of Protein-Protein Interactions.

  2023cites this paper
• Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer.

  2023cites this paper
• Advances in the Molecular Landscape of Lung Cancer Brain Metastasis

  2023cites this paper
• Receptor tyrosine kinases: biological functions and anticancer targeted therapy

  2023cites this paper
• Methylseleninic acid overcomes gefitinib resistance through asparagine-MET-TOPK signaling axis in non-small cell lung cancer cells.

  2023cites this paper
• An Observatory for the MET Oncogene: A Guide for Targeted Therapies

  2023cites this paper
• Understanding how MSCs reverse radiation-induced fibrosis: HGF vs. TGF-B1

  2023cites this paper
• Histopathological Evaluation of Cancer Tendency in the Buccal Mucosa of Aged Albino Rats (Histological and Immunohistochemical Study)

  2023cites this paper
• Melanoma and Glioblastoma—Not a Serendipitous Association

  2023cites this paper
• Multiomics Study of a Novel Naturally Derived Small Molecule, NSC772864, as a Potential Inhibitor of Proto-Oncogenes Regulating Cell Cycle Progression in Colorectal Cancer

  2023cites this paper
• Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics

  2023cites this paper
• Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach

  2023cites this paper
• Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy

  2022cites this paper
• Non-coding RNAs and glioma: Focus on cancer stem cells

  2022cites this paper
• Assessment of boundary discrimination performance in a printed phantom

  2022cites this paper
• Discovery of novel conjugates of quinoline and thiazolidinone urea as potential anti-colorectal cancer agent

  2022cites this paper
• An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer

  2022cites this paper
• The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma

  2022cites this paper
• MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development

  2022cites this paper
• Novel Cellular Therapies for Hepatocellular Carcinoma

  2022cites this paper
• Opportunities and challenges of targeting c-Met in the treatment of digestive tumors

  2022cites this paper
• Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use

  2022cites this paper
• The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery

  2022cites this paper
• Recent advances in systemic therapy for hepatocellular carcinoma

  2022cites this paper
• MACC1 promotes pancreatic cancer metastasis by interacting with the EMT regulator SNAI1

  2022cites this paper
• Cancer cell targeting by CAR-T cells: A matter of stemness

  2022cites this paper
• The Structure, Function and Regulation of Protein Tyrosine Phosphatase Receptor Type J and Its Role in Diseases

  2022cites this paper
• MET∆14 promotes a ligand-dependent, AKT-driven invasive growth

  2022cites this paper
• B cell linker protein (BLNK) is a regulator of Met receptor signaling and trafficking in non-small cell lung cancer

  2022cites this paper
• Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease

  2022cites this paper
• hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers

  2022cites this paper
• A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations

  2021cites this paper
• The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study

  2021cites this paper
• Resistance to Molecularly Targeted Therapies in Melanoma

  2021cites this paper
• A receptor-antibody hybrid hampering MET-driven metastatic spread

  2021cites this paper
• Loss of Apc cooperates with activated oncogenes to induce liver tumor formation in mice.

  2021cites this paper
• PARP1: Structural insights and pharmacological targets for inhibition.

  2021cites this paper
• Immune Checkpoint Inhibitors in the Treatment of HCC

  2021cites this paper
• HGF/c-Met Signalling in the Tumor Microenvironment.

  2021cites this paper
• Analysis of the Protein–Protein Interaction Network Identifying c-Met as a Target of Gigantol in the Suppression of Lung Cancer Metastasis

  2021cites this paper
• Novel Ion Channel Targets and Drug Delivery Tools for Controlling Glioblastoma Cell Invasiveness

  2021cites this paper
• MET Exon 14 Skipping Alterations in Non-small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances

  2021cites this paper
• The Role of Decorin and Biglycan Signaling in Tumorigenesis

  2021cites this paper
• Photoreactive Molecular Glue for Enhancing the Efficacy of DNA Aptamers by Temporary-to-Permanent Conjugation with Target Proteins.

  2021cites this paper
• ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation

  2021cites this paper
• Author Correction: ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation

  2021cites this paper
• An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)

  2021cites this paper
• Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

  2021cites this paper
• Synthesis of 4-methyl-2-phenyl-N-(pyridin-2-yl) thiazole-5-carboxamide

  2021cites this paper
• 간세포암종의 병리진단에 대한 최신 지견

  2021cites this paper
• HGF/MET Axis Induces Tumor Secretion of Tenascin-C and Promotes Stromal Rewiring in Pancreatic Cancer

  2021cites this paper
• Targeting HGF/c-MET Axis in Pancreatic Cancer

  2020cites this paper
• Nanobodies in cancer.

  2020cites this paper
• Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression

  2020cites this paper
• The impact of autophagy during the development and survival of glioblastoma

  2020cites this paper
• Spiromyrrhenes A–D: unprecedented diterpene–sesquiterpene heterodimers as intermolecular [4 + 2] cycloaddition products from Resina Commiphora that inhibit tumor stemness in esophageal cancer

  2020cites this paper
• Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

  2020cites this paper
• Discovery of 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy)-N,N-diethylpiperidine-1-carboxamide as kinase inhibitor for the treatment of colorectal cancer.

  2020cites this paper
• Cancer of Unknown Primary Site: Real Entity or Misdiagnosed Disease?

  2020cites this paper
• c-Met as a potential therapeutic target in triple negative breast cancer

  2020cites this paper
• Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivo

  2020cites this paper
• The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.

  2020cites this paper
• Molecular therapies for HCC: Looking outside the box.

  2020cites this paper
• The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma

  2020cites this paper
• Investigation of metastasis-associated in colon cancer-1 genetic variants in the development and clinicopathologcial characteristics of uterine cervical cancer in Taiwanese women

  2020cites this paper
• FCHSD2 controls oncogenic ERK1/2 signaling outcome by regulating endocytic trafficking

  2020cites this paper
• Synthesis and biological evaluation of quinoxaline derivatives as specific c-Met kinase inhibitors.

  2020cites this paper
• Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy.

  2020cites this paper
• Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma

  2019cites this paper
• NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies

  2019cites this paper
• Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape

  2019cites this paper
• Verteporfin blocks Clusterin which is required for survival of gastric cancer stem cell by modulating HSP90 function

  2019cites this paper
• Management of Non-Clear Cell Renal Cell Carcinoma

  2019cites this paper
• Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma

  2019cites this paper
• In a Rat Model of Acute Liver Failure, Icaritin Improved the Therapeutic Effect of Mesenchymal Stem Cells by Activation of the Hepatocyte Growth Factor/c-Met Pathway

  2019cites this paper
• Meta-analysis of functional expression and mutational analysis of c-Met in various cancers.

  2019cites this paper
• Effect of c-Met and CD44v6 Expression in Resistance to Chemotherapy in Esophageal Squamous Cell Carcinoma

  2019cites this paper
• MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.

  2019cites this paper